RAPP

Insider Trades

Name	Value	Action	Price	Current Price
Bredt DavidChief Scientific Officer $119k8.5k shares SellJul 15, 2025 $14.00 --
Bredt DavidChief Scientific Officer $3.2k200 shares SellAug 15, 2025 $15.79 --
Bredt DavidChief Scientific Officer $124k8.3k shares SellAug 15, 2025 $14.98 --
Gault CherylChief Operating Officer $192k5k shares SellSep 8, 2025 $38.33 --
Young Wendy B.Director $79k3.5k shares BuySep 11, 2025 $22.60 --
Paul Steven MDirector $693k28.3k shares BuySep 12, 2025 $24.50 --

News

seekingalpha.comRapport Therapeutics, Inc. (RAPP) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcriptseekingalpha.comJun 8

globenewswire.comRapport Therapeutics to Participate in the Jefferies Global Healthcare Conference and Goldman Sachs 47th Annual Global Healthcare Conferenceglobenewswire.comMay 20

zacks.comRapport Therapeutics, Inc. (RAPP) Reports Q1 Losszacks.comMay 7

globenewswire.comRapport Therapeutics Reports First Quarter 2026 Financials and Provides Business Updateglobenewswire.comMay 7

globenewswire.comModalités de mise à disposition du rapport financier annuel 2025globenewswire.comApr 30

Trade RAPP

About Rapport Therapeutics, Inc. Common Stock

Rapport Therapeutics, Inc. functions as a clinical-phase biopharmaceutical enterprise, concentrating its efforts on discovering and developing innovative small-molecule therapeutics for individuals living with central nervous system (CNS) disorders. Its flagship product candidate, RAP-219, is an experimental small molecule precisely designed to inhibit TARPy8-containing AMPARs with exceptional potency (picomolar affinity). This promising compound aims to treat focal epilepsy and a range of other neurological conditions, including peripheral neuropathic pain and bipolar disorder. The company's pipeline further includes RAP-199, another molecule targeting TARPy8, which boasts distinct chemical and pharmacokinetic profiles. Moreover, Rapport is advancing several nicotinic acetylcholine receptor (nAChR) programs, such as an a6 nAChR therapy for chronic pain and an a9a10 nAChR treatment intended for hearing impairments. Formed in 2022 under the initial name Precision Neuroscience NewCo, Inc., the company adopted its current identity as Rapport Therapeutics, Inc. in October 2022, and its operations are based in Boston, Massachusetts.

CEO: Abraham N. Ceesay
IPO Date: Jun 7, 2024

Market Data

Open: $37.16
High: $37.31
Low: $35.81
Volume: 180.7K
52W High: $42.27
52W Low: $10.51

Valuation

Market Cap: $1.3B
Enterprise Value: $1.3B

Financials

Free Cash Flow: $-88M
Revenue: $0
Net Income: $-111M
Cash: $53M
Debt: $11M

Events

EarningsAug 6

EPS est. -0.9